246 related articles for article (PubMed ID: 27206678)
1. Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Orucevic A; Heidel RE; Bell JL
Breast Cancer Res Treat; 2016 Jun; 157(3):427-35. PubMed ID: 27206678
[TBL] [Abstract][Full Text] [Related]
2. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
[TBL] [Abstract][Full Text] [Related]
3. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
4. The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Penault-Llorca F; Filleron T; Asselain B; Baehner FL; Fumoleau P; Lacroix-Triki M; Anderson JM; Yoshizawa C; Cherbavaz DB; Shak S; Roca L; Sagan C; Lemonnier J; Martin AL; Roché H
BMC Cancer; 2018 May; 18(1):526. PubMed ID: 29728098
[TBL] [Abstract][Full Text] [Related]
5. Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy.
Enewold L; Geiger AM; Zujewski J; Harlan LC
Breast Cancer Res Treat; 2015 May; 151(1):149-56. PubMed ID: 25859924
[TBL] [Abstract][Full Text] [Related]
6. 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
Parsons BM; Landercasper J; Smith AL; Go RS; Borgert AJ; Dietrich LL
Breast Cancer Res Treat; 2016 Sep; 159(2):315-26. PubMed ID: 27507245
[TBL] [Abstract][Full Text] [Related]
7. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
Dodson A; Okonji D; Assersohn L; Rigg A; Sheri A; Turner N; Smith I; Parton M; Dowsett M
Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
[TBL] [Abstract][Full Text] [Related]
8. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
9. First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Dieci MV; Guarneri V; Giarratano T; Mion M; Tortora G; De Rossi C; Gori S; Oliani C; Merlini L; Pasini F; Bonciarelli G; Griguolo G; Orvieto E; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P
Oncologist; 2018 Mar; 23(3):297-305. PubMed ID: 29133514
[TBL] [Abstract][Full Text] [Related]
10. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
[TBL] [Abstract][Full Text] [Related]
11. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
12. The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
Crolley VE; Marashi H; Rawther S; Sirohi B; Parton M; Graham J; Vinayan A; Sutherland S; Rigg A; Wadhawan A; Harper-Wynne C; Spurrell E; Bond H; Raja F; King J
Breast Cancer Res Treat; 2020 Apr; 180(3):809-817. PubMed ID: 32170635
[TBL] [Abstract][Full Text] [Related]
13. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
Partin JF; Mamounas EP
Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
Roberts MC; Miller DP; Shak S; Petkov VI
Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
[TBL] [Abstract][Full Text] [Related]
16. Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK.
Loncaster J; Armstrong A; Howell S; Wilson G; Welch R; Chittalia A; Valentine WJ; Bundred NJ
Eur J Surg Oncol; 2017 May; 43(5):931-937. PubMed ID: 28111076
[TBL] [Abstract][Full Text] [Related]
17. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
18. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage.
Yu-Qing Y; Lei W; Mei-Ling H; Jing-Jing X; Mei-Chen W; Jiang W; Jun-Sheng H; Rui L; Nan-Lin L
Exp Mol Pathol; 2019 Jun; 108():150-155. PubMed ID: 31026440
[TBL] [Abstract][Full Text] [Related]
20. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Turashvili G; Brogi E; Morrow M; Hudis C; Dickler M; Norton L; Wen HY
Breast Cancer Res Treat; 2017 Aug; 165(1):65-76. PubMed ID: 28577081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
